Changes

no edit summary
Line 304: Line 304:  
|Acute myeloid leukaemia with KMT2A rearrangement
 
|Acute myeloid leukaemia with KMT2A rearrangement
 
|Disease
 
|Disease
|Megan Piazza, Ph.D., Yiming Zhong, Ph.D., Shashi Shetty, Ph.D.
+
|
 
|
 
|
 
|
 
|
Line 312: Line 312:  
|
 
|
 
|
 
|
|
+
|Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); KMT2A-MLLT3
|
+
|Megan Piazza, Ph.D., Yiming Zhong, Ph.D., Shashi Shetty, Ph.D.
|
+
|Complete
|
+
|03/01/2021-MS (re-review)
 
|
 
|
 
|-
 
|-
Line 328: Line 328:  
|
 
|
 
|
 
|
 +
|Acute Myeloid Leukemia (AML) with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM
 +
|Gordana Raca MD PhD, University of Southern California, Los Angeles
 +
|Complete
 
|
 
|
|
+
|Need permission for figure? Update WHO?
|
  −
|
  −
|
   
|-
 
|-
 
|Acute myeloid leukaemia with NUP98 rearrangement
 
|Acute myeloid leukaemia with NUP98 rearrangement
Line 344: Line 344:  
|
 
|
 
|
 
|
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
|
+
|NEW (No Prior)
 
|-
 
|-
 
|Acute myeloid leukaemia with NPM1 mutation
 
|Acute myeloid leukaemia with NPM1 mutation
 
|Disease
 
|Disease
|Xinjie Xu, PhD, FACMG
+
|
 
|
 
|
 
|
 
|
Line 360: Line 360:  
|
 
|
 
|
 
|
 +
|Acute Myeloid Leukemia (AML) with Mutated NPM1
 +
|Xinjie Xu, PhD, FACMG
 +
|Complete
 
|
 
|
|
+
|Add WHO reference
|
  −
|
  −
|
   
|-
 
|-
 
|Acute myeloid leukaemia with CEBPA mutation
 
|Acute myeloid leukaemia with CEBPA mutation